Advertisement

Topics

Esanex Announces Successful End-of-Phase 2 Meeting for SNX-5422 in Neuroendocrine Tumors

07:00 EDT 4 Oct 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
-- Agreement reached with FDA on key elements of Phase 3 trial – -- SNX-5422 Granted Orphan Drug Designation -- Esanex, Inc., a clinical stage company developing Heat Shock Protein inhibitors for the treatm...

Other Sources for this Article

MacDougall Biomedical Communications
Rob Kloppenburg and Shai Biran, Ph.D, 1-781-235-3060
rkloppenburg@macbiocom.com
sbiran@macbiocom.com

NEXT ARTICLE

More From BioPortfolio on "Esanex Announces Successful End-of-Phase 2 Meeting for SNX-5422 in Neuroendocrine Tumors"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...